Centrus Energy (LEU) JP Morgan Energy, Power and Renewables Conference summary
Event summary combining transcript, slides, and related documents.
JP Morgan Energy, Power and Renewables Conference summary
3 Feb, 2026Industry trends and market outlook
Fukushima in 2011 led to global plant shutdowns and a downturn, but the sector has since rebounded.
Russia's invasion of Ukraine highlighted the need for energy independence, boosting nuclear investment.
Carbon-free energy goals have increased interest in nuclear as a baseload solution.
Nuclear enrichment remains a highly restricted, technology-intensive segment with few global players.
Barriers to entry in enrichment are high, limiting new competitors for years.
Business positioning and differentiation
Operates in the most constrained part of the nuclear fuel cycle: uranium enrichment.
Only publicly traded enrichment provider, with a licensed HALEU facility in Ohio.
Only U.S. enrichment technology currently operating, with unique dual-use (civilian and defense) capabilities.
First-mover advantage in HALEU production for advanced reactors.
Segment breakdown and growth strategy
Two segments: LEU (84% of revenue, broker-trader model) and CTS (16%, focused on HALEU and growth).
CTS is expected to outpace LEU in growth, potentially flipping the revenue mix within five years.
Addressable market across commercial, advanced reactors, and national security could reach $10 billion by 2035.
LEU segment has long-term supply/offtake agreements, with $1 billion backlog and $900 million in conditional LOIs through 2040.
Latest events from Centrus Energy
- Exclusive U.S. HALEU enricher, expanding to meet surging demand as Russian supply exits.LEU
Investor presentation11 Feb 2026 - Record revenue, $900M HALEU award, and $3.8B backlog drive growth and expansion plans.LEU
Q4 202511 Feb 2026 - Q2 net income surged to $30.6M on $189M revenue, with pension liabilities sharply reduced.LEU
Q2 20242 Feb 2026 - Q3 revenue up 12% to $57.7M, net loss $5M, $3.8B backlog, major DOE awards, and regulatory risks.LEU
Q3 202418 Jan 2026 - Poised for growth as the top U.S. uranium enricher, backed by strong contracts and federal support.LEU
Investor Presentation30 Dec 2025 - Revenue up 38% to $442M, with $3.7B backlog and major DOE wins amid regulatory risks.LEU
Q4 202417 Dec 2025 - Virtual meeting to elect directors, approve pay, and ratify auditors, with strong governance focus.LEU
Proxy Filing1 Dec 2025 - Shareholders are being solicited to vote on annual meeting matters with no fee required.LEU
Proxy Filing1 Dec 2025 - Strong revenue growth, cash reserves, and strategic investments drive U.S. uranium leadership.LEU
Proxy Filing1 Dec 2025